A Phase 1 Trial of LIB-01 in Healthy Participants.

Summary

The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetics of LIB-01 in healthy male participants. The main questions it aims to answer are: * How safe and tolerable is LIB-01 when given once or repeatedly at different dose levels. * What are the pharmacokinetic characteristics of LIB-01 Participants will receive LIB-01 and be followed up for safety and pharmacokinetics by: * Adverse events * ECG * Blood sampling for laboratory parameters and pharmacokinetic analysis

Timeline

Start

2023-08-25

Primary completion

2024-04-23

Completion

2024-05-29

Outcome

Met primary endpoint

release “Dicots avslutade kliniska fas 1-studie visar att bolagets läkemedelskandidat LIB-01 har en mycket god säkerhetsprofil vilket var studiens primära syfte.” dicotpharma.com ↗

Drugs

Indications